Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23182622 | 1.00 | LMNA (0.44) | LMNAMEN1HTTKMT2ASMN1; SMN2 | |
| SCHEMBL29771571 | 1.00 | LMNA (0.44) | LMNAMEN1HTTKMT2ASMN1; SMN2 | |
| SCHEMBL24099533 | 1.00 | LMNA (0.44) | LMNAMEN1HTTKMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28638820 | 0.99 | LMNA (0.43) | LMNAMEN1HTTKMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28638822 | 0.99 | LMNA (0.43) | LMNAMEN1HTTKMT2ASMN1; SMN2 | |
| SCHEMBL25871719 | 0.88 | GAA (0.41) | MEN1KMT2AGAAL3MBTL1TP53 | |
| SCHEMBL23486089 | 0.80 | TP53 (0.46) | LMNAMEN1HTTKMT2ASMN1; SMN2 | |
| SCHEMBL22078042 | 0.80 | TP53 (0.46) | LMNAMEN1HTTKMT2ASMN1; SMN2 | |
| SCHEMBL24811011 | 0.79 | ACACA (0.39) | LMNAHTTKMT2AGAAL3MBTL1 | |
| SCHEMBL29771538 | 0.79 | ACACA (0.39) | LMNAHTTKMT2AGAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582634-B2 | Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine | NEUROCRINE BIOSCIENCES, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12383536-B2 | CRF receptor antagonists and methods of use | NEUROCRINE BIOSCIENCES, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-12128033-B2 | Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine | NEUROCRINE BIOSCIENCES, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| US-20240238257-A1 | SYNTHETIC METHODS FOR PREPARATION OF 4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-[(1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL]-5-METHYL-N-PROP-2-YNYL-1,3-THIAZOL-2-AMINE | SANOFI (FR) | 2024-07-18 | — | — | US | disclosed |
| CN-118252829-A | CRF receptor antagonists and methods of use | 纽罗克里生物科学有限公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20230286932-A1 | SYNTHETIC METHODS FOR PREPARATION OF 4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-[(1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL]-5-METHYL-N-PROP-2-YNYL-1,3-THIAZOL-2-AMINE | NEUROCRINE BIOSCIENCES, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230233534-A1 | SYNTHETIC METHODS FOR PREPARATION OF 4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-[(1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL]-5-METHYL-N-PROP-2-YNYL-1,3-THIAZOL-2-AMINE | NEUROCRINE BIOSCIENCES, INC. | 2023-07-27 | — | — | US | disclosed |
| CN-116322668-A | Synthetic method for preparing 4- (2-chloro-4-methoxy-5-methylphenyl) -N- [ (1S) -2-cyclopropyl-1- (3-fluoro-4-methylphenyl) ethyl ] -5-methyl-N-prop-2-ynyl-1, 3-thiazol-2-amine | 纽罗克里生物科学有限公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4164604-A2 | SYNTHETIC METHODS FOR PREPARATION OF 4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-[(1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL]-5-METHYL-N-PROP-2-YNYL-1,3-THIAZOL-2-AMINE | Neurocrine Biosciences, Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| US-20220409592-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2022-12-29 | — | — | US | disclosed |
| CN-115087647-A | Synthetic method for preparing 4- (2-chloro-4-methoxy-5-methylphenyl) -N- [ (1S) -2-cyclopropyl-1- (3-fluoro-4-methylphenyl) ethyl ] -5-methyl-N-prop-2-alkynyl-1, 3-thiazol-2-amine | 纽罗克里生物科学有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-114502162-A | CRF receptor antagonists and methods of use | 纽罗克里生物科学有限公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021250468-A2 | SYNTHETIC METHODS FOR PREPARATION OF 4-(2-CHLORO-4-METHOXY-5- METHYLPHENYL)-V-[(LS)-2-CYCLOPROPYL-L-(3-FLUORO-4-METHYLPHENYL)ETHYL]-5-METHYL-V-PROP-2-YNYL-L,3-THIAZOL-2-AMINE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021111179-A1 | SYNTHETIC METHOD FOR PREPARATION OF 4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-[(1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL]-5-METHYL-N-PROP-2-YNYL-1,3-THIAZOL-2-AMINE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12128033-B2 | Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine | CYP21A2, NR5A1, HSD3B1 | LMNA 2695/4885MEN1 107/4885HTT 2363/4885 |
| US-20230233534-A1 | SYNTHETIC METHODS FOR PREPARATION OF 4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-[(1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL]-5-METHYL-N-PROP-2-YNYL-1,3-THIAZOL-2-AMINE | CYP21A2, NR5A1, HSD3B1 | LMNA 2695/4885MEN1 107/4885HTT 2363/4885 |
| US-12383536-B2 | CRF receptor antagonists and methods of use | CRHR1, CRHR2, MC2R | LMNA 3541/4885MEN1 1501/4885HTT 2696/4885 |
| US-20220409592-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | CRHR1, CRHR2, MC2R | LMNA 3541/4885MEN1 1501/4885HTT 2696/4885 |
| US-20240238257-A1 | SYNTHETIC METHODS FOR PREPARATION OF 4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-[(1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL]-5-METHYL-N-PROP-2-YNYL-1,3-THIAZOL-2-AMINE | CYP21A2, NR5A1, HSD3B1 | LMNA 2463/4885MEN1 125/4885HTT 2212/4885 |
| US-20230286932-A1 | SYNTHETIC METHODS FOR PREPARATION OF 4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-[(1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL]-5-METHYL-N-PROP-2-YNYL-1,3-THIAZOL-2-AMINE | CYP21A2, NR5A1, HSD3B1 | LMNA 2463/4885MEN1 125/4885HTT 2212/4885 |
| US-12582634-B2 | Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine | CYP21A2, CYP11B1, NR5A1 | LMNA 1093/4885MEN1 188/4885HTT 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.